Retatrutide
Metabolic
Also known as: LY3437943, Triple G
Triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors for enhanced weight loss and metabolic improvements.
- Dose in studies
- 1-12 mg weekly (titrate up slowly)
- Frequency
- Once weekly
- Cycle length
- Continuous under medical supervision
- Half-life
- 6 days
- Research level
- 4/5 – Well researched
Frequently asked questions about Retatrutide
What is Retatrutide?
Triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors for enhanced weight loss and metabolic improvements.
What is the half-life of Retatrutide?
The half-life of Retatrutide is 6 days.
What dosage of Retatrutide has been studied?
Described in research: 1-12 mg weekly (titrate up slowly), frequency: Once weekly. This is not a medical recommendation.
How long is a Retatrutide cycle?
Typical cycle length in studies: Continuous under medical supervision.
What are the side effects of Retatrutide?
Nausea: Very common (30-40%), especially during dose escalation. Slow titration and anti-nausea medication significantly reduce severity. Usually improves within 4-6 weeks. · Diarrhea: Reported by ~20% of users. GI motility changes from triple receptor activation. Usually transient. · Decreased appetite: Intended effect but can be extreme. Ensure adequate protein intake (1.5g/kg/day minimum) to…
How well researched is Retatrutide?
Well researched (4/5). Large phase 3 trials or regulatory approval; long-term data still limited.